TrialOpen forum infectious diseases2025

Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline.

Karam Mounzer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.